Literature DB >> 16121312

Genetics of pulmonary arterial hypertension: current and future implications.

C Gregory Elliott1.   

Abstract

Idiopathic pulmonary arterial hypertension (formerly primary pulmonary hypertension) can affect more than one member of the same family. In the past 25 years scientists have exposed the inheritance pattern and a major element of the molecular basis for inherited pulmonary arterial hypertension. Familial pulmonary arterial hypertension is inherited as an autosomal dominant trait with incomplete penetrance (i.e., several individuals inherit a predisposition to the disease, but never express it). Mutations in the gene that codes for bone morphogenetic protein receptor type II (BMPR-II) are a major predisposition for the development of pulmonary arterial hypertension. These mutations are present in at least half of familial cases of pulmonary arterial hypertension and 10 to 25% of idiopathic pulmonary arterial hypertension patients. Mutations in the gene that codes for activin receptor-like kinase (ALK 1), another transforming growth factor beta (TGF-beta) cell surface receptor, appear responsible for the rare occurrence of pulmonary arterial hypertension in patients with hereditary hemorrhagic telangiectasia. These discoveries coupled with other basic investigations offer opportunities for advances in the management of pulmonary arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16121312     DOI: 10.1055/s-2005-916150

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  9 in total

1.  High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension.

Authors:  Joy D Cogan; Michael W Pauciulo; Amy P Batchman; Melissa A Prince; Ivan M Robbins; Lora K Hedges; Krista C Stanton; Lisa A Wheeler; John A Phillips; James E Loyd; William C Nichols
Journal:  Am J Respir Crit Care Med       Date:  2006-05-25       Impact factor: 21.405

Review 2.  Genetics and mediators in pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Clin Chest Med       Date:  2007-03       Impact factor: 2.878

3.  Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension.

Authors:  Revathi Rajkumar; Kazuhisa Konishi; Thomas J Richards; David C Ishizawar; Andrew C Wiechert; Naftali Kaminski; Ferhaan Ahmad
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-01-15       Impact factor: 4.733

Review 4.  Vascular remodeling in pulmonary hypertension.

Authors:  Larissa A Shimoda; Steven S Laurie
Journal:  J Mol Med (Berl)       Date:  2013-01-19       Impact factor: 4.599

Review 5.  Lung Circulation.

Authors:  Karthik Suresh; Larissa A Shimoda
Journal:  Compr Physiol       Date:  2016-03-15       Impact factor: 9.090

Review 6.  Genetics of pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd; John A Phillips
Journal:  Semin Respir Crit Care Med       Date:  2009-07-24       Impact factor: 3.119

7.  Heritable forms of pulmonary arterial hypertension.

Authors:  Eric D Austin; James E Loyd
Journal:  Semin Respir Crit Care Med       Date:  2013-09-13       Impact factor: 3.119

8.  Hemodynamic and clinical onset in patients with hereditary pulmonary arterial hypertension and BMPR2 mutations.

Authors:  Nicole Pfarr; Justyna Szamalek-Hoegel; Christine Fischer; Katrin Hinderhofer; Christian Nagel; Nicola Ehlken; Henning Tiede; Horst Olschewski; Frank Reichenberger; Ardeschir H A Ghofrani; Werner Seeger; Ekkehard Grünig
Journal:  Respir Res       Date:  2011-07-29

9.  Implication of overexpression of dishevelled-associated activator of morphogenesis 1 (Daam-1) for the pathogenesis of human Idiopathic Pulmonary Arterial Hypertension (IPAH).

Authors:  Shun Yanai; Megumi Wakayama; Haruo Nakayama; Minoru Shinozaki; Hisayuki Tsukuma; Naobumi Tochigi; Tetsuo Nemoto; Tsutomu Saji; Kazutoshi Shibuya
Journal:  Diagn Pathol       Date:  2017-03-14       Impact factor: 2.644

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.